switching between glp-1 agonists ada GLP‐1 receptor in clinical practice: Expert consensus and practical guidance GLP-1 Agonists - What is

Description

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimers disease

To ensure the robustness of our MR findings, we conducted a series of sensitivity analyses designed to comprehensively assess the underlying MR assumptions

and (iii) phenotype-stratified, clinically interpretable decision-support tools that can help identify which patients are most likely to benefit from time-bounded metabolic optimization before conception or ART

[DOI] [PubMed] [Google Scholar] 13.Ruan Y, Jiang S, Gericke A

Consistent with previous studies, cotadutide outperformed GLP-1 alone (40 nmol/kg/day liraglutide) in achieving maximal weight loss in obese mice, and this was attributed to the increased energy expenditure (77)